Jazz Pharmaceuticals revenue and financials
$231.39Change from previous close: −1.97%Absolute change: −$4.65
In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.88%
- 2025 vs 2024
- Net margin
- -8.3%
- 2024: 13.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,356 | 1,396 | 1,092 | 1,272 | 779 | 900 | 776 | 799 | 693 | 592 |
| Depreciation and amortization | 41.6 | 32.8 | 30.4 | 30.3 | 26.7 | 18.7 | 15.3 | 15.2 | 13.1 | 11.8 |
| Capital expenditure | -58.8 | -38.1 | -24.0 | -29.0 | -27.6 | -15.0 | -40.1 | -20.4 | -29.0 | -9.7 |
| Investing cash flow | -1,510 | -508 | -163 | -446 | -5,212 | — | — | — | — | — |
| Financing cash flow | -873 | 20.5 | -305 | -529 | 3,971 | — | — | — | — | — |
| Share repurchases | -125 | -311 | -270 | -0.1 | 0.0 | -147 | -301 | -524 | -98.8 | -278 |
| Debt issued | 0.0 | 981 | 0.0 | 0.0 | 5,191 | — | — | — | — | — |
| Debt repaid | -781 | -606 | -31.0 | -582 | -1,321 | — | — | — | — | — |
| Effect of exchange rates | 6.6 | -1.7 | 1.1 | -6.2 | -3.2 | — | — | — | — | — |
| Net change in cash | -1,021 | 907 | 625 | 290 | -466 | — | — | — | — | — |
| Free cash flow | 1,297 | 1,358 | 1,068 | 1,243 | 751 | — | — | — | — | — |
| Levered free cash flow | 1,355 | 1,436 | 1,056 | 1,125 | -138 | — | — | — | — | — |